My prediction, the week of April 5th, all hell breaks
My prediction, the week of April 5th, all hell breaks loose. This week we will get dribbles and the following week, boom!
Okay, hold me to it and BTW, NASH 700 numbers are a real big deal. The reason is real simple, we are not a one trick pony. It's what CDiddy said once, take Leronlimab for NASH, side effects include reduction in:
AA Amyloidosis
Acute Respiratory Distress Syndrome
Allergies (anaphylactic shock)
Alopecia Areata
Alzheimer's
Amyotrophic Lateral Sclerosis
Angioedema
Anthrax
Aplastic Anemia
Asthma
Atherosclerosis
Atopic Dermatitis
Cancer
Castleman Disease
Celiac Disease
Coeliac Disease
Chronic Fatigue Syndrome/Myalgic Encephalomyelitis
Chronic Inflammatory Demyelinating Polyneuropathy
Chronic Kidney Disease (due to inflammation)
Chronic Traumatic Encephalopathy
COPD
COVID-19 (and other coronaviruses)
COVID-19 longhaulers syndrome (PASC)
Crohn's Disease
Colitis
Cystic Fibrosis (anti-inflammatory in combo with CFTR modulators)
Dermatomyositis
Diabetes (type 1 and 2)
Duchenne Muscular Dystrophy
Emphysema
Endometriosis
Eosinophilic Esophagitis
Epilepsy (reduction in frequency and severity)
Fibromyalgia
FMF Related Amyloidosis
Fragile X Syndrome
Gout
Grave’s Disease
Guillain-Barre Syndrome
GVHD
Hashimoto’s Thyroiditis
Henoch–Schönlein Purpura
Hepatitis (autoimmune)
HIV
Huntington's Disease
Idiopathic Pulmonary Fibrosis
Immune Thrombocytopenia
Inclusion Body Myositis
Inflammatory Bowel Disease
Influenza (severe)
Kawasaki Syndrome
Lambert-Eaton Syndrome
Lewy Body Dementia
Lupus
Lyme Disease
Lymphedema
Marshall’s syndrome (PFAPA)
Mesenteric Panniculitis
Miller Fisher Syndrome
Multiple Sclerosis
Myasthenia Gravis
Myocarditis
Necrotizing Autoimmune Myopathy
Neurofibromatosis
Osteoarthritis
Osteomyelitis
Parkinson's Disease
Pemphigus
Peyronie's Disease (treatment of underlying autoimmune condition)
Pneumonia
Polymyositis
Post-Myocardial Infarction Syndrome
Psoriasis
Pulmonary Arterial Hypertension
Pulmonary Fibrosis
Rett Syndrome
Rheumatic Fever
Rheumatoid Arthritis
Sarcoidosis
Scleroderma
Sepsis
Sickle Cell Disease (anti-inflammatory and anti-hypercoagulability effect)
Sjogren’s Syndrome
Still’s Disease
Stroke
Trigeminal Neuralgia
Tuberculosis
Vasculitis
Wegener’s Granulomatosis
4
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Dividend Declaration Reflects Confidence First Industrial Realty Trust, folks, just put another office stamp on their ongoing reliability quest—and I'm talking dividends. They're shelling out a tidy $0.50 per share for Q4 2026, with stockholders due to see the cash on January 19, 2027. That's like clockwork precision, showing a steadiness in what some call the unruly...
Continue Reading
Solid-State Dreams Meet AI Magic Ah, the sweet sound of synergy. ISU Specialty Chemical and Ares Materials are brewing up something that could shake the battery world—solid-state cells juiced by AI-driven polymer magic. Now, the tech and finance geeks are likely on the edge of their seats. This isn't just another run-of-the-mill collab; it's a heavyweight match to speed...
Continue Reading
Stellus Capital's Upcoming Financial Reveal: Stakes and Details November's not just bringing the cold breezes, folks; it's also ushering in the much-anticipated financial digits of Stellus Capital Investment Corporation's third quarter of 2026. Mark your calendars for November 9, after the stock market wraps up, when Stellus will drop its operational performance stats for...
Continue Reading
Big Bucks for Cyber Missteps When it rains, it pours—or in the case of ILC Dover, it’s a downpour of $13 million they’re forking over to settle a gnarly cybersecurity debacle. If you blinked, you might miss this hefty payout marking the biggest recovery under the Department of Justice’s Civil Cybersecurity Fraud program. So, what's the fuss about? Well, it's got...
Continue Reading
LONGi Surpasses New BNEF Barriers with Ease Alright, let's dig into the meat of the matter today. LONGi has snagged its 10th straight spot in BloombergNEF's (BNEF) Tier 1 list of global energy storage manufacturers. And mind you, that's no small potatoes, especially with stricter financing demands rearing their hefty heads this quarter. Non-Recourse Financing: A Tougher...
Continue Reading
Old-School Radios Meet Cutting-Edge 5G When I hear about a company linking their old-school tech with shiny new 5G jazz, skepticism kicks in fast. But then comes this announcement: Askey and Icom America are joining forces to bring 5G networks with integrated two-way radio systems to various sectors—like a classic combo meal with a tech twist. The key audience? Utility...
Continue Reading
What's Really Going On Here? Here's the skinny: Halper Sadeh LLC, that hard-hitting investor rights law firm, is poking their noses into some potential red flags over at a few companies you might have heard of—Lumentum Holdings (NASDAQ:LITE), Range Resources (NYSE:RRC), and Surgery Partners (NASDAQ:SGRY). They're sniffing around transactions that might leave the regular...
Continue Reading
A Solid Quarter for CVS Health CVS Health Corporation has once again turned heads with its third-quarter 2026 results. When you're pulling $108.4 billion in quarterly revenue, up 5.4% from last year, folks notice. Adjusted earnings hit $2.09 per share, climbing a respectable 30% from $1.60 the year before. The cherry on top? A big fat boost in 2026 guidance, signaling...
Continue Reading
Even in this digital age, customer service sometimes feels as outdated as a rotary phone. But along comes Parloa, sharpening its edge in North America by shaking hands with Deloitte Canada to overhaul the typical customer service experience. This isn't just another handshake; it's a full-fledged mission to rewire customer interactions through innovative AI-powered...
Continue Reading
Drilling Challenges and Initial Observations Folks, it's a roller coaster out there—A2Gold just wrapped up a gritty round of drilling at their Eastside Gold-Silver Project near Tonopah, Nevada. They've punched through five reverse circulation (RC) holes, totaling 1,936 meters, all while battling tough conditions. You could say they've truly earned their stripes in the...
Continue Reading
Top 5 Most Recently Viewed Articles
CMIT Solutions Strengthens IT Services with Strategic Acquisition Nation's Leading IT Provider Enhances Corporate Portfolio with Automation and Cybersecurity Expertise In a significant move to enhance its service offerings, CMIT Solutions has recently acquired Velox Systems, a managed service provider renowned for its innovative solutions and expertise in advanced...
Continue Reading
NextEra Energy to Reveal 2025 Financial Results NextEra Energy, Inc. (NYSE: NEE) has recently revealed its plans to disclose the fourth-quarter and full-year financial results for 2025. This announcement is set to take place before the opening of the New York Stock Exchange, specifically on Tuesday, January 27, 2026. Investors and interested parties can expect a news...
Continue Reading
Donaldson Company Reports Progress in First Quarter Donaldson Company, Inc. (NYSE: DCI), recognized globally for its innovative filtration solutions, has released its financial results for the first quarter of fiscal year 2025. The company celebrated a remarkable achievement in both sales and earnings, revealing GAAP net earnings of $99 million, a rise from $92.1 million...
Continue Reading
Understanding the Challenges of China's Economy Scott Bessent, an influential figure in U.S. economic policy, recently voiced significant concerns regarding the structure of China’s economy. He characterized it as one of the most unbalanced economies in contemporary history, a viewpoint that has formed the basis of discussions around global trade relations. China's...
Continue Reading
Acrivon Therapeutics to Reveal Exciting Clinical Developments Acrivon Therapeutics, Inc. is on the verge of announcing significant updates regarding its clinical pipeline, specifically focusing on ACR-368 and ACR-2316. This Massachusetts-based biotechnology company leverages its unique Generative Phosphoproteomics AP3 platform to develop precision medicines aimed at...
Continue Reading